

# **Knobbe Martens Olson & Bear LLP**

*Intellectual Property Law*

2040 Main Street  
Fourteenth Floor  
Irvine, CA 92614  
Tel 949-760-0404  
Fax 949-760-9502  
www.kmob.com

**Che S. Chereskin**  
Patent Agent

August 2, 2010

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: Title: DEVICE, KIT AND METHOD FOR PULSING BIOLOGICAL SAMPLES  
WITH AN AGENT AND STABILISING THE SAMPLE SO PULSED  
Letters Patent No. 7,700,276  
Issued: April 20, 2010  
Our Reference: DECLE35.005APC

Dear Sir:

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As some of the errors cited in the Certificate of Correction were incurred through the fault of the Applicant, the required payment of \$100 will be made via the EFS Web. Please charge any additional fees to our Deposit Account No. 11-1410.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP



Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Customer No. 20995

Enclosures

9443048  
073010

**San Diego**  
619-235-8550

**San Francisco**  
415-954-4114

**Los Angeles**  
310-551-3450

**Riverside**  
951-781-9231

**Seattle**  
206-405-2000

**Washington, DC**  
202-640-6400

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

**PATENT NO.** : 7,700,276  
**APPLICATION NO.** : 10/563,503  
**ISSUE DATE** : April 20, 2010  
**INVENTOR(S)** : Stordeur, et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 4, Line 35, "nucleic add stabilising" should be changed to --nucleic acid stabilising--

Column 4, Line 42, "of step (f using" should be changed to --of step (f) using--

Column 6, Line 28, "are selected from one" should be changed to --selected from one--

Column 6, Line 29, "tetanous toxoid," should be changed to --tetanus toxoid,--

Column 7, Line 13, "the RNAlater reagent" should be changed to --the RNA later reagent--

Column 7, Line 17, NaCl alone or an" should be changed to --NaCl alone or an--

Column 8, Line 61, "I.42-43). Therefore," should be changed to --1.42-43). Therefore,--

Column 11, Line 14, "is tetanous toxoid." should be changed to --is tetanus toxoid.--

Column 18, Line 59, "directly of indirectly" should be changed to --directly or indirectly--

Column 19, Line 2, "with an identical similar" should be changed to --with an identical/similar--

Column 19, Line 53, "the pulsed/nonpulsed cells," should be changed to --the pulsed/non-pulsed cells,--

Column 26, Line 8, "the same individual," should be changed to --the same individuals,--

Column 26, Line 32, "tetradecyltrimethylammonium oxalate" should be changed to

--tetradecyltrimethylammonium oxalate--

Column 29, Line 21, "(dendritic cells," should be changed to --(dendritic cells,--

Column 29, Line 64, "epitope-specifiq CTLs" should be changed to --epitope-specific CTLs--

Column 30, Line 44, "is damaged Would" should be changed to --is damaged would--

Column 30, Line 48, "subclinical episodes of" should be changed to --sub-clinical episodes of--

Column 31, Lin 15, "Pure<sup>TM</sup>0 instrument" should be changed to -- Pure<sup>TM</sup> instrument--

Column 31, Line 45, "of the PAXgene<sup>TM</sup>0 tube's" should be changed to -- of the PAXgene<sup>TM</sup> tube's--

### MAILING ADDRESS OF SENDER:

Che Swyden Chereskin, Ph.D.  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
2040 Main Street, 14<sup>th</sup> Floor  
Irvine, California 92614

DOCKET NO. DECLE35.005APC

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.** : 7,700,276  
**APPLICATION NO.** : 10/563,503  
**ISSUE DATE** : April 20, 2010  
**INVENTOR(S)** : Stordeur, et al.

Page 2 of 2

Column 33, Line 25, "and IFN $\gamma$  mRNAs" should be changed to -- and IFN- $\gamma$  mRNAs--

Column 35, Line 9, "quantfication errors," should be changed to --quantification errors,--

Column 35, Line 64, "in vitro incubaton" should be changed to --in vitro incubation--

Column 36, Line 25, "to monitor alloreactive" should be changed to --to monitor alloreactive--

Column 37, Line 14, "6FaM-" should be changed to --6Fam- --

Column 38, Lines 15-16, "dilution of PCR" should be changed to --dilutions of PCR--

9442585  
073010

**MAILING ADDRESS OF SENDER:**

Che Swyden Chereskin, Ph.D.  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
2040 Main Street, 14<sup>th</sup> Floor  
Irvine, California 92614

DOCKET NO. DECLE35.005APC